Y-mAbs Therapeutics Dirección

Dirección controles de criterios 2/4

We currently do not have sufficient information about the CEO.

Información clave

Mike Rossi

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	6.4yrs
Promedio de permanencia en la Junta Directiva	6.3yrs

Actualizaciones recientes de la dirección

Recent updates

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

May 12

Y-mAbs Therapeutics (NASDAQ:YMAB) Is In A Good Position To Deliver On Growth Plans

Dec 09

CEO

Mike Rossi (52 yo)

less than a year

Permanencia

Mr. Michael Rossi, also known as Mike, serves as Chief Executive Officer, President & Director of Y-mAbs Therapeutics, Inc. since November 06, 2023. He has been Director at Nucleus RadioPharma, Inc. He had...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Gad	Founder	9yrs	US$1.44m	0.99% $ 6.4m
Bo Kruse	Executive VP	8.8yrs	US$1.15m	0.42% $ 2.7m
Susan Smith	Senior VP & Chief Commercial Officer	2.3yrs	US$833.60k	0.0097% $ 62.5k
Michael Rossi	CEO, President & Director	less than a year	sin datos	sin datos
Joris Wiel Wilms	Senior VP & COO	6.4yrs	sin datos	0.014% $ 87.3k
Torben Lund-Hansen	Senior VP & CTO	8.3yrs	sin datos	0.12% $ 759.0k
Courtney Dugan	Vice President of Investor Relations	no data	sin datos	sin datos
Vignesh Rajah	Senior VP & Chief Medical Officer	3.8yrs	US$724.92k	0.019% $ 124.9k

6.4yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de YMAB es experimentado (6.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Gad	Founder	9yrs	US$1.44m	0.99% $ 6.4m
Michael Rossi	CEO, President & Director	less than a year	sin datos	sin datos
James Healy	Independent Chairman of the Board	6.4yrs	US$224.86k	0.059% $ 379.2k
David Gill	Independent Director	6.3yrs	US$242.58k	0% $ 0
Mary Tagliaferri	Director	less than a year	sin datos	sin datos
Johan Wedell-Wedellsborg	Independent Director	8.6yrs	US$220.08k	0% $ 0
Ashutosh Tyagi	Independent Director	6.4yrs	US$220.08k	0% $ 0
Laura Hamill	Independent Director	3.8yrs	US$225.30k	0% $ 0
Gérard Ber	Independent Director	5.3yrs	US$217.58k	0% $ 0

6.3yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: YMAB's board of directors are considered experienced (6.3 years average tenure).

Y-mAbs Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024

Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer

Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors

Founder exercised options to buy US$370k worth of stock.

Founder recently sold US$1.0m worth of stock

Founder notifies of intention to sell stock

Recent updates

Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024

Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Consensus estimates of losses per share improve by 42%

Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Y-mAbs Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Price target increased by 9.3% to US$13.67

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Founder exercised options to buy US$370k worth of stock.

Founder recently sold US$1.0m worth of stock

Founder notifies of intention to sell stock

Founder recently sold US$795k worth of stock

Founder notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Reiterates Financial Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Y-mAbs Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Y-mAbs Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective from November 6, 2023

Y-mAbs Therapeutics, Inc. Announces Publication of Naxitamab-Based Chemoimmunotherapy in Patients with Chemoresistant High-Risk Neuroblastoma

Consensus EPS estimates upgraded to US$0.70 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Revenue and earnings growth

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Y-mAbs Therapeutics, Inc. Announces DANYELZA (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in Brazil

Consensus revenue estimates increase by 27%

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Price target increased by 11% to US$10.50

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Updates Financial Guidance for the Full-Year 2023

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Consensus estimates of losses per share improve by 14%

Price target decreased by 15% to US$9.14

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Y-mAbs Therapeutics, Inc. and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab

Rosen Law Firm Encourages Y-Mabs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB

Price target decreased to US$10.88

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Y-mAbs Therapeutics, Inc. Announces National Medical Products Administration in China Has Granted Danyelza 40Mg/10Ml Conditional Approval

Y-mAbs Therapeutics, Inc. Announces Complete Response Letter for Omburtamab Biologics License Application

Price target decreased to US$12.00

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2022

Y-mAbs Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Consensus EPS estimates fall by 18%

Y-mAbs Therapeutics Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

Y-mAbs Therapeutics, Inc Announces Pivotal Data for Omburtamab

Y-Mabs Therapeutics, Inc. Announces Scheduling of Fda Advisory Committee Meeting for Omburtamab

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

Consensus EPS estimates fall by 16%

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Y-mAbs Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Y-mAbs Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Y-mAbs Therapeutics, Inc. Announces Initiation of its First Clinical Trial with SADA Construct

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Y-mAbs Therapeutics, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for Omblastys (Omburtamab) for the Treatment of Neuroblastoma for Priority Review

Y-mAbs Therapeutics, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for Omblastys (Omburtamab) for the Treatment of Neuroblastoma for Priority Review

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

Y-mAbs Therapeutics, Inc Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint

Consensus revenue estimates increase by 16%

Consensus EPS estimates fall by 19%

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

Y-mAbs Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022